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Mycobacterium tuberculosis is a concern in patients with human immunodeficiency virus (HIV) infection.
Rifampin (RIF), an agent used against M. tuberculosis, is contraindicated with most HIV protease inhibitors.
Atazanavir (ATV) has clinical efficacy comparable to a standard of care regimen in naive patients and, when
dosed with low-dose ritonavir (RTV), also in treatment-experienced patients. We evaluated here the safety and
pharmacokinetics of ATV, resulting from three regimens of ATV, RTV, and RIF in 71 healthy subjects. The
pharmacokinetics for ATV and RTV were assessed after 6 and 10 days of dosing with ATV 400 mg (n 53) and
with ATV-RTV at 300 and 100 mg (ATV/RTV 300/100; n  52), respectively. Steady-state pharmacokinetics for
ATV, RTV, RIF, and desacetyl-rifampin (des-RIF) were measured after 10 days of dosing of ATV/RTV/RIF
300/100/600 (n  17), ATV/RTV/RIF 300/200/600 (n  17), or ATV/RTV/RIF 400/200/600 (n  14). An RIF
600-alone arm was enrolled as a control group (n  18). With ATV/RTV/RIF 400/200/600, ATV area under the
concentration-time curve values were comparable, but the Cmin values were lower relative to ATV 400 alone.
ATV exposures were substantially reduced for the other RIF-containing regimens relative to ATV 400 alone and
for all regimens relative to ATV/RTV 300/100 alone. RIF and des-RIF exposures were 1.6- to 2.5-fold higher
than with RIF 600 alone. The incidence of grade 3/4 alanine aminotransferase/aspartate aminotransferase
values was limited to 1 subject each in both the ATV/RTV/RIF 300/200/600 and the ATV/RTV/RIF 400/200/600
treatments. Coadministration of ATV with RIF was safe and generally well tolerated. Since ATV exposures were
reduced in all regimens, ATV and RIF should not be coadministered at the dosing regimens studied.
Mycobacterium tuberculosis infection is a bacterial infection
spread via the respiratory contact and is a substantial cause of
morbidity and mortality in humans. This infection is of partic-
ular concern in individuals who are also infected with human
immunodeficiency virus (HIV). Coinfection may contribute to
a worsening of the course of HIV or M. tuberculosis infection
and an acceleration of mortality (4). Treatment regimens con-
taining rifampin (RIF) are particularly important in develop-
ing countries, since they are highly effective and generally less
expensive than alternative regimens.
HIV protease inhibitors (PIs) are commonly included as a
key component of highly active antiretroviral therapy, often in
combination with two nucleoside reverse transcriptase inhibi-
tors for the treatment of HIV. The coadministration of RIF is
contraindicated with all currently marketed HIV PIs except for
full-strength and schedule ritonavir (RTV) at 600 mg twice
daily (BID). This dose and schedule of RTV is seldom used
due to intolerability issues, but RTV is frequently used at a low
dose (100 mg once daily [QD] or BID) to enhance plasma
concentrations of other HIV PIs (10, 13, 17). In addition, the
package insert of RTV recommends that alternate antimyco-
bacterial agents such as rifabutin should be considered.
RIF is a potent inducer of both intestinal and hepatic
CYP3A4 (3). All HIV PIs are substrates for CYP3A4 (for a
review, see reference 2). As a nonspecific inducer, RIF has also
been reported to induce the phase I metabolic enzymes
CYP1A2 and CYP2C9, the phase II metabolic enzymes UDP-
glucuronyltransferases and sulfotransferases (3), and the efflux
pump system P-glycoprotein (7), which have all been impli-
cated in PI disposition.
The PI atazanavir (ATV) is also a CYP3A4 substrate (5, 14),
so a substantial decrease in ATV exposures can be anticipated
with coadministration with RIF. To overcome the inductive
effect of RIF on CYP450-mediated metabolism, coadministra-
tion of RTV is an option with a potential clinical application.
Other studies have shown that the addition of RTV to a RIF-
based combination was able to compensate for the inductive
effects on saquinavir (19), nelfinavir (1), and lopinavir (11).
The primary objective of the present study was to assess the
pharmacokinetics of ATV resulting from three regimens of
ATV/RTV/RIF relative to those of ATV with or without RTV
in healthy subjects. Secondary objectives were to study the
pharmacokinetics of RTV and RIF and to assess the safety of
the various drug combinations.
(This study was presented in part at the 12th Conference on
Retroviruses and Opportunistic Infections, Boston, Mass., 22
to 25 February 2005.)
MATERIALS AND METHODS
Study design. This was an open-label, multiple-dose, randomized, drug inter-
action study in healthy volunteers. Subjects had to give informed consent, and the
study protocol was approved by the IRB Institutional Review Board, Wychen,
The Netherlands. Subjects underwent screening evaluations to determine eligi-
bility within 21 days prior to study enrollment. Subjects were admitted to the
clinical facility the evening prior to the initial dose of ATV (day1). Seventy-one
subjects were randomized to one of four treatment sequences on day 1 (Fig. 1).
* Corresponding author. Mailing address: Department of Clinical
Pharmacy, 864 Radboud UMC Nijmegen, Geert Grooteplein 10, 6525
GA Nijmegen, The Netherlands. Phone: 31 24 3616406. Fax: 31 24
3668755. E-mail: D.Burger@akf.umcn.nl.
† Supplemental material for this article may be found at http://aac
.asm.org/.
3336
 o
n
 N
ovem
ber 2, 2012 by Universiteitsbibliotheek
http://aac.asm
.org/
D
ow
nloaded from
 
Fifty-three subjects received ATV 400 mg QD on days 1 through 6, followed by
ATV and RTV at 300 and 100 mg, respectively (ATV/RTV 300/100), QD on
days 7 through 16 (n 52). These subjects then received one of three treatments
from days 17 to 26 as randomized on day 1: ATV/RTV/RIF 300/100/600 (n 
17), ATV/RTV/RIF 300/200/600 (n  17), or ATV/RTV/RIF 400/200/600 (n 
14). An additional 18 subjects underwent procedures identical to those who
received study drug on days 1 to 16, except that they did not receive study drug
or submit to a pharmacokinetic evaluation on days 1 through 16. This group
received RIF 600 alone on days 17 to 26 and underwent both trough and serial
(day 26) pharmacokinetic sampling during this period. All study drugs were
administered within 5 min after completing a light meal (300 kcal, 20% fat).
Subjects participated as outpatients receiving directly observed therapy except
for the days of full pharmacokinetic sampling and contiguous days, when they
were housed in the clinic. The subjects entered the clinic the evening prior to full
pharmacokinetic sampling (days 5, 15, and 25) and remained in the clinic until
the sampling period was completed (the morning of days 7 and 17 and discharge
on day 27). Blood samples were collected for pharmacokinetic analysis up to 24 h
postdose on days 6, 16, and 26 and on additional days for trough levels. Safety
assessments were performed at selected times throughout the study. Subjects
were closely monitored for adverse events (AEs) throughout the study.
Study subjects. Healthy subjects as determined by medical history, physical
examination, 12-lead electrocardiogram, and clinical laboratory evaluations were
eligible to participate in the study. Negative results from a Mantoux tuberculin
test and, if necessary, a chest X-ray were utilized to rule out tuberculosis.
Subjects met all of the following criteria for inclusion in the study: a signed
informed consent form; no clinically significant deviations from normal in med-
ical history, physical examination, electrocardiogram exam (ECG), or clinical
laboratory determinations; a body mass index (i.e., weight in kilograms/[height in
meters]2) of 18 to 30 kg/m2, inclusive; body weight of 60 kg for males and 50
kg for females; and ages 18 to 50, inclusive.
Exclusion criteria included the following: any sound medical, psychiatric,
and/or social reason as determined by the investigator; evidence of organ dys-
function or any clinically significant deviation from normal in physical examina-
tion, vital signs, ECG, or clinical laboratory determinations; positive urine screen
for drugs of abuse either at screening or before dosing; positive blood screen for
hepatitis B surface antigen and/or hepatitis C antibody; positive blood screen for
HIV type 1 or 2 antibody; positive serum or urine for -HCG; Mantoux test of
15 mm or 0 to 15 mm with chest X-ray positive for tuberculosis; creatinine
clearance of 80 ml/min; liver enzymes (total bilirubin, alkaline phosphatase,
aspartate aminotransferase [AST], alanine aminotransferase [ALT]) above the
upper limit of normal; use of any agent, within 8 weeks of dosing, known to
induce or inhibit drug-metabolizing enzymes (e.g., cimetidine); use of any pre-
scription drugs or over-the-counter acid controllers within 4 weeks prior to
enrollment; use of any other drugs, including over-the-counter medications or
herbal preparations, within 1 week prior to enrollment (an exception was made
for investigator-approved use of ibuprofen); use of an oral, injectable, or im-
plantable hormonal contraceptive agent within 1 month of enrollment; use of St.
John’s Wort (hypericum) within 4 weeks prior to study enrollment or throughout
the study; and the consumption of grapefruit- or Seville orange-containing prod-
ucts within 1 week of study entry and throughout the study.
Safety. Safety assessments were based on medical review of AE reports and
the results of vital sign measurements, ECGs, physical examinations, and clinical
laboratory tests. The incidence of AEs was tabulated and reviewed for potential
significance and clinical importance. AE data were obtained by volunteering of
information by the subjects and constant monitoring and daily questioning of the
subjects by the study staff, as well as by the investigator review of vital signs,
ECGs, laboratory, and other data.
Pharmacokinetics. Blood samples were collected for intensive pharmacoki-
netic evaluation on day 6 (ATV 400), day 16 (ATV/RTV 300/100), and day 26
(ATV/RTV/RIF/des-RIF) prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12,
16, and 24 h after dosing. In addition, trough blood samples were collected on
selected days during study drug administration. Blood samples, 3 ml for RIF/
des-RIF and 4 ml for ATV/RTV analysis, were collected into tripotassium
EDTA tubes. The tubes were inverted gently a few times and were centrifuged
for 10 min at approximately 1,000  g in a refrigerated centrifuge (at ca. 5°C) to
separate the cellular elements from plasma. The plasma samples were then
assayed by validated liquid chromatography-tandem mass spectrometry methods.
The range of the standard curve was 5 to 5,000 ng/ml for ATV and RTV and 50
to 35,000 ng/ml for RIF and des-RIF. The between-run variability and within-run
variability expressed as the coefficient of variation (CV) was no greater than 3.7
and 18.9% for ATV, 4.9 and 12.1% for RTV, 3.3 and 6.6% for RIF, and 4.7 and
7.6% for des-RIF, respectively.
The plasma concentration-time data were analyzed by a noncompartmental
method using Kinetica version 4.2 (Thermo Corp., Philadelphia, PA). The peak
plasma concentration (Cmax) and the time to reach Cmax (Tmax) were recorded
directly from experimental observations for each treatment period. The slope of
the terminal phase of the plasma profile, K, was determined by log-linear re-
gression of at least three datum points, which yielded a minimum mean square
error using no weighting factor. The absolute value of K was used to estimate the
apparent terminal half-life (T-half) by the following calculation: T-half  ln2/K.
The area under the plasma concentration-time curve over a dosing interval
[AUC(TAU)] was calculated by trapezoidal and log-trapezoidal summations,
where TAU  24 h.
Statistical methods. To estimate the effects of RIF and RTV on the pharmaco-
kinetics of ATV, general linear model analyses were performed on the log(Cmax),
the log[AUC(TAU)], and the log(Cmin) of ATV. The factors in the analyses were
treatment as a fixed effect and subject as a repeated-measure effect. Point
estimates and 90% confidence intervals (90% CI) were calculated to compare
the treatments ATV/RTV 300/100, ATV/RTV/RIF 300/100/600, ATV/RTV/RIF
300/200/600, and ATV/RTV/RIF 400/200/600 versus ATV 400 and the treat-
ments ATV/RTV/RIF 300/100/600, ATV/RTV/RIF 300/200/600, and ATV/
RTV/RIF 400/200/600 versus ATV/RTV 300/100. Similar analyses were also
FIG. 1. Study design. S, screening; E, enrollment; R, randomization; DC, discharge.
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performed for RTV. The effects of ATV and RTV on the pharmacokinetics of
RIF and des-RIF were also evaluated by analyses of variance on the log(Cmax)
and log[AUC(TAU)]. Point estimates and 90% CI values were calculated to
compare treatments ATV/RTV/RIF 300/100/600, ATV/RTV/RIF 300/200/600,
and ATV/RTV/RIF 400/200/600 versus treatment RIF 600. The estimated dif-
ferences on the log scale were converted back to the original scale to obtain
ratios of geometric means on the original scale. Geometric means estimated
from the general linear model are also referred as adjusted geometric means
(adjusted by the factors included in the model). No adjustments were made for
multiplicity. For summary statistics and analysis of the Cmin data, BLQ (for below
limit of quantification) values were set to half of the lower limit of quantification
(LLQ) for the analytical method used in the present study. All statistical analyses
were performed by using SAS/STAT version 8.2.
Although the sample size was not based on statistical power considerations, 14
subjects in each of the treatment groups provided 82% confidence that the
estimated ratios of the ATV AUC geometric means when ATV is administered
alone or with RTV versus when ATV is administered with RTV and RIF is
within 20% of the true population value. In order to allow for dropouts, 18
subjects were enrolled in each treatment sequence.
RESULTS
Subject accrual and demographics. A total of 71 subjects
were enrolled into the present study. Of the 71 subjects ran-
domized to treatment in the present study, 65 (92%) com-
pleted treatment and 6 (8%) discontinued from the study early
after receiving study medication. Four subjects discontinued
the study due to AEs (hypotension, exanthema/pruritis, dizzi-
ness, and vomiting; n  1 for each). The other two subjects
discontinued due to poor compliance with the study protocol
(antisocial behavior; n  1) and withdrawal of consent to
accept an employment opportunity (n  1).
Forty-seven (66%) of the subjects were male, and twenty-
four (34%) were female. The mean (standard deviation [SD])
age of all subjects was 31 (SD  10) years. Sixty-three (89%)
of the subjects were Caucasian, four (6%) were black, and four
(6%) were classified as “other.” “Other” races included mixed
black/Asian, mixed Caucasian/black, and American Indian/
Alaskan Native (two subjects). The mean body mass index of
all subjects was 24 (SD  3) kg/m2. The mean body weight for
all subjects was 79 (SD  11) kg.
Pharmacokinetics. The mean plasma concentration-time
profiles of ATV in the five treatment groups are presented in
Fig. 2A (see also the supplemental material). Summary statis-
tics for ATV pharmacokinetic parameters are listed in. Table 1
Finally, the adjusted geometric means, ratios of adjusted geo-
metric means, and 90% CI values for the ratios of AUC(TAU),
Cmax, and Cmin are summarized in Table 2.
The coadministration of RIF reduced the exposures to ATV
considerably. Relative to ATV 400 or ATV/RTV 300/100
alone, in all treatments with the exception of ATV/RTV/RIF
400/200/600, the Cmax, AUC, and Cmin for ATV were statisti-
cally significantly lower (Table 2).
Relative to ATV 400, the ATV AUC and Cmax values were
reduced ca. 30 to 60% with a greater decrease in Cmin values.
With ATV/RTV/RIF 400/200/600, the ATV AUC and Cmax
values were comparable to those observed when ATV was
administered alone at 400 mg. However, ATV Cmin values
were still significantly reduced by ca. 60%.
Relative to ATV/RTV 300/100, ATV/RTV/RIF 300/100/600
and ATV/RTV/RIF 300/200/600 resulted in a reduction of ca.
40 to 70% in ATV AUC and Cmax, with a 90% decrease in
Cmin values. With ATV/RTV/RIF 400/200/600, AUC and Cmax
were only moderately decreased by ca. 29 and 13%, respec-
tively, but with again a 90% decrease in Cmin values.
The AUC and Cmin values of ATV when coadministered
with RTV at a dose of ATV/RTV 300/100 were 1.5- and 3.8-
fold higher than the corresponding values at ATV 400 alone,
respectively. However, the Cmax values for the two groups were
similar. Trough values for ATV suggested that subjects were at
steady state for ATV by the end of each treatment period.
The effect of RIF on RTV pharmacokinetics was almost
identical to the effect observed for ATV (Fig. 2B). RTV ex-
posures (Cmax and AUC) were decreased by ca. 80% with
ATV/RTV/RIF 300/100/600 compared to RTV exposures
noted with the ATV/RTV 300/100 regimen. Specifically, ad-
justed geometric means for Cmax were reduced from 1,877 to
390 ng/ml and for AUC from 10,213 to 1,516 ng · h/ml. Con-
versely, RTV AUC values with ATV/RTV/RIF 300/200/600
FIG. 2. (A) Steady-state mean plasma concentration-time profiles
for ATV. (B) Steady-state mean plasma concentration-time profiles
for RTV. The SD values are indicated.
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mg were comparable to the values noted with ATV/RTV 300/
100 administration. The adjusted geometric means for RTV
AUC were 11,313 to 11,995 ng · h/ml compared to 10,213 ng ·
h/ml. Cmax values were ca. 60% higher than those observed
with ATV/RTV 300/100 administration. Specifically, the ad-
justed geometric means for RTV Cmax were 3,005 to 3,147
ng/ml compared to 1,877 ng/ml. All treatments with RIF
showed a 50% decrease in T-half and a substantial decrease
(80%) in Cmin values for RTV.
Even though RTV trough concentrations were below the
level of quantification for most subjects receiving RIF with
ATV/RTV 300/100 and for some subjects receiving ATV/
RTV/RIF 300/200/600 and ATV/RTV/RIF 400/200/600, it is
expected that, considering the pharmacokinetics of RTV, the
steady state would have been achieved with 10 days of dosing.
Because we included a separate group of subjects who took
RIF 600 QD alone, it was possible to estimate the effect of
adding ATV/RTV on RIF AUC and Cmax. The mean plasma
concentration-time profiles of RIF in the four groups are pre-
sented in Fig. 3A. Summary statistics for RIF pharmacokinetic
parameters are listed in Table 3. The adjusted geometric
means, ratios of adjusted geometric means, and 90% CI values
for the ratios of AUC(TAU) and Cmax are summarized in
Table 4 (Cmin of RIF is below the detection limit). RIF expo-
sures were increased on coadministration of all ATV/RTV/
RIF treatments relative to RIF 600 alone. The increase in
AUC of RIF ranged from ca. 49 to 64% with ATV/RTV/RIF
treatments compared to RIF 600 alone. The increase in RIF
Cmax ranged from ca. 32 to 39% after ATV/RTV/RIF treat-
ments relative to RIF 600 alone. All increases in exposures
were statistically significant. The T-half values of RIF were
comparable across all treatment groups and thus did not ap-
pear to be affected by the coadministration of ATV and RTV.
Finally, the effect of ATV/RTV on des-RIF pharmacokinet-
ics was similar to the effect observed for RIF (Fig. 3B). The
coadministration of ATV/RTV/RIF in all treatment groups
resulted in increased des-RIF exposures of 2.2- to 2.7-fold for
AUC and 2-fold for Cmax compared to the exposures produced
TABLE 1. Summary statistics for ATV pharmacokinetic parametersa
Pharmacokinetic parameter
Result with regimen:
ATV 400
(day 6; n  52)
ATV/RTV 300/100
(day 16; n  48)
ATV/RTV/RIF
300/100/600
(day 26; n  16)
ATV/RTV/RIF
300/200/600
(day 26; n  17)
ATV/RTV/RIF
400/200/600
(day 26; n  14)
Geometric mean AUC(TAU)
(ng  h/ml) (CV%)
28,204.3 (38) 44,517.1 (33) 12,661.2 (33) 20,691.2 (34) 24,041.9 (35)
Geometric mean Cmax
(ng/ml) (CV%)
5,337.1 (24) 5,135.7 (31) 2,611.0 (33) 3,342.2 (33) 3,906.4 (30)
Geometric mean Cmin
(ng/ml)b (CV%)
186.9 (104) 707.3 (58) 18.1 (58) 42.7 (81) 52.9 (78)
Median Tmax (h) (min, max) 2.0 (1, 4) 2.5 (2, 4) 2.8 (2, 4) 2.5 (2, 4) 2.5 (2, 4)
Mean T-half (h) (SD) 6.3 (2.4) NEc 3.4 (0.7) 3.2 (0.6) 3.5 (0.8)
a BLQ values were replaced by 1/2LLQ  2.5 ng/ml. Day 6, ATV 400; day 16, ATV/RTV 300/100; day 26, ATV/RTV/RIF 300/100/600, ATV/RTV/RIF 300/200/600,
or ATV/RTV/RIF 400/200/600. n  number of subjects.
b 24 h postdose.
c NE, not evaluated.
TABLE 2. Summary of statistical analyses of ATV pharmacokinetic parameters relative to ATV 400 and to ATV/RTV 300/100a
Pharmacokinetic
parameter
Adjusted geometric mean for regimen: Ratio of adjusted geometric mean pointestimate (90% CI)
ATV/RTV/RIF
300/100/600
(day 26; n  16)
ATV 400
(day 6; n  52)
ATV/RTV 300/100
(day 16; n  48) Day 26 vs day 6 Day 26 vs day 16
AUC(TAU) (ng  h/ml) 11,626.9 27,169.4 41,725.9 0.43 (0.37, 0.49) 0.28 (0.25, 0.32)
Cmax (ng/ml) 2,330.5 5,272.6 5,010.8 0.44 (0.39, 0.50) 0.47 (0.41, 0.53)
Cmin (ng/ml) 15.9 181.1 685.6 0.09 (0.07, 0.11) 0.02 (0.02, 0.03)
ATV/RTV/RIF
300/200/600
(day 26; n  17)
ATV 400
(day 6; n  52)
ATV/RTV 300/100
(day 16; n  48)
AUC(TAU) (ng  h/ml) 18,863.6 27,169.4 41,725.9 0.69 (0.62, 0.78) 0.45 (0.41, 0.50)
Cmax (ng/ml) 3,171.1 5,272.6 5,010.8 0.60 (0.54, 0.67) 0.63 (0.57, 0.70)
Cmin (ng/ml) 40.6 181.1 685.6 0.22 (0.18, 0.28) 0.06 (0.05, 0.07)
ATV/RTV/RIF
400/200/600
(day 26; n  14)
ATV 400
(day 6; n  52)
ATV/RTV 300/100
(day 16; n  48)
AUC(TAU) (ng  h/ml) 29,890.8 27,169.4 41,725.9 1.10 (0.90, 1.35) 0.72 (0.60, 0.85)
Cmax (ng/ml) 4,313.8 5,272.6 5,010.8 0.82 (0.67, 1.00) 0.86 (0.71, 1.04)
Cmin (ng/ml) 74.4 181.1 685.6 0.41 (0.29, 0.58) 0.11 (0.08, 0.15)
a n  number of subjects.
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on administration of RIF alone. Specifically, the increases in
adjusted geometric mean AUC were 5,535 to 6,640 ng · h/ml
versus 2,493 ng · h/ml and for adjusted geometric mean Cmax
were 1,285 to 1,390 ng/ml versus 674 ng/ml. Similar to RIF, the
Cmin for des-RIF was found to be below the detection limit.
Safety. There were no deaths or serious AEs in the study
(Table 5). The majority of AEs (89%) were mild in intensity
and resolved prior to discharge. As noted above, four subject
discontinuations were due to the AEs: hypotension, xanthema
and pruritis, dizziness, and vomiting, all with onset during the
ATV/RTV 300/100 treatment. The most frequently occurring
AEs (10% of subjects) were chromaturia, headache, fatigue,
ocular icterus, dizziness, abdominal pain, urinary tract infec-
tion, jaundice, nausea, dyspepsia, vomiting, myalgia, and hy-
perhidrosis. AE occurrence (% of subjects) was comparable
across treatments, with incidence of jaundice (icterus), head-
aches, fatigue, and dizziness being more prevalent in treat-
ments ATV 400 and ATV/RTV 300/100 and chromaturia be-
ing more prevalent in RIF-containing regimens. Incidence of
transaminase elevation was infrequent and not treatment re-
lated (Table 5).
DISCUSSION
The objective of this study was to evaluate the effect of RIF
on the pharmacokinetics of ATV. ATV is a CYP3A4 substrate
(5), (14), and RIF is a potent CYP3A4 inducer (3). Since both
drugs may be used in combination, a substantial decrease in
ATV concentrations was anticipated upon coadministration
with RIF. To counteract the inductive effect of RIF, the addi-
tion of RTV, a potent CYP3A4 inhibitor, was studied as part
of three alternate dosing strategies.
There were two control arms in the study, with the aim of
obtaining ATV exposures comparable to ATV alone (ATV
400) and/or ATV with RTV (ATV/RTV 300/100) when ATV,
RTV, and RIF were administered together. In the ATV/RTV/
RIF 300/100/600 treatment regimen, the combination of 300/
100 ATV/RTV was studied with 600 mg of RIF. The ATV/
RTV 300/100 regimen is currently being used in treatment-
experienced HIV-positive patients. This regimen is also used in
patients receiving efavirenz, since ATV with RTV was ob-
served to sufficiently counteract the inductive effect of efa-
virenz, a moderately potent CYP3A4 inducer (18).
Since RIF is considered to be a more potent inducer of
CYP3A4 than efavirenz (8), two other regimens, ATV/RTV/
RIF 300/200/600 and ATV/RTV/RIF 400/200/600, were also
FIG. 3. (A) Steady-state mean plasma concentration-time profiles
for RIF in groups. (B) Steady-state mean plasma concentration-time
profiles for des-RIF. The SD values are indicated.
TABLE 3. Summary statistics for RIF pharmacokinetic parametersa
Pharmacokinetic parameter
Result with regimen:
ATV/RTV/RIF 300/100/
600 (day 26; n  16)
ATV/RTV/RIF 300/200/
600 (day 26; n  17)
ATV/RTV/RIF 400/200/
600 (day 26; n  14)
RIF 600 (day 26;
n  14)
Geometric mean AUC(TAU) (ng  h/ml) (CV%) 46,571.8 (36) 49,483.9 (47) 51,257.0 (21) 31,267.7 (46)
Geometric mean Cmax (ng/ml) (CV%) 10,613.1 (35) 11,222.6 (37) 10,983.3 (18) 8,057.6 (45)
Geometric mean Cmin (ng/ml)
b (CV%) 25.0 (0) 25.0 (0) 25.0 (0) 25.0 (0)
Median Tmax (h) (min, max) 2.5 (2, 4) 2.5 (2, 4) 2.5 (2, 4) 2.5 (2, 4)
Mean T-half (h) (SD) 1.6 (0.2) 1.7 (0.5) 1.7 (0.4) 1.5 (0.2)
a BLQ values were replaced by 1/2LLQ  25 ng/ml. Day 26, ATV/RTV/RIF 300/100/600, ATV/RTV/RIF 300/200/600, or ATV/RTV/RIF 400/200/600; day 26, RIF
600. n  number of subjects.
b 24 h postdose.
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studied. In these regimens, the dose of RTV was increased to
200 mg in anticipation of the ability of RTV to decrease the
clearance and thereby increase the Cmin values of ATV with
only a modest effect on ATV Cmax.
It has been reported that 400 mg of ATV and 200 mg of
RTV increases the exposures (AUC) and Cmin values of ATV
by approximately 2.3- and 10-fold, respectively, relative to the
400-mg regimen alone (15). Therefore, the ATV/RTV/RIF
400/200/600 regiment was selected with the expectation of pro-
viding the most robust exposures to ATV compared to the
ATV/RTV/RIF 300/100/600 and ATV/RTV/RIF 300/200/600
regimens.
The results showed that relative to ATV at 400 mg alone,
ATV exposures (Cmax, AUC, and Cmin) were decreased con-
siderably with ATV/RTV/RIF 300/100/600 or ATV/RTV/RIF
300/200/600. Conversely, with ATV/RTV/RIF 400/200/600, the
AUC of ATV was increased by 10%. However, the Cmin of
ATV was still decreased by 59% relative to that observed with
400 mg alone. Because it is generally accepted that Cmin is the
most relevant pharmacokinetic parameter predicting antiviral
activity (2) for HIV PIs and Cmin in all of the tested regimens
was significantly reduced, none of these adjusted regimens of
ATV/RTV can be recommended together with RIF.
Relative to ATV/RTV 300/100, ATV exposures (Cmax,
AUC, and Cmin) were substantially decreased in all treatment
regimens with coadministration of RIF and therefore, as noted
above, none of the adjusted regimens of ATV/RTV can be
recommended with RIF.
When dosed with RTV, examination of ATV profiles showed
that the concentrations noted with ATV/RTV/RIF 300/200/
600 and ATV/RTV/RIF 400/200/600 appeared to be superim-
posable with ATV concentrations observed with administra-
tion of ATV at 400 mg alone until approximately 12 h (Fig.
2A). After the 12-h time point, the concentrations declined
steeply. This observation suggests that an additional dose of
ATV/RTV at approximately 12 h may alleviate the reduction
in ATV concentrations seen with the coadministration of RIF.
RTV exposures (AUC) when dosed at 200 mg with ATV
and RIF were generally comparable to RTV exposures ob-
served with ATV 300/100 ATV/RTV alone. In contrast, RTV
exposures when dosed at 100 mg with ATV and RIF were very
low relative to RTV exposures observed with 300/100 ATV/
RTV. The Cmin values for RTV were decreased substantially in
all treatment regimens upon coadministration of RIF com-
pared to those observed with ATV/RTV 300/100 alone.
Interestingly, exposures (AUC) to RIF (50 to 60%) and
des-RIF (two- to threefold) were higher when RIF was coad-
ministered with ATV/RTV compared to administration of RIF
600 alone. The mechanism for the increase in RIF and des-RIF
concentrations when coadministered with ATV and RTV is
unknown. ATV is a CYP3A4 substrate and inhibitor. It is also
a weak inhibitor of P-gp with a 50% inhibitory concentration of
TABLE 4. Summary of statistical analyses of RIF pharmacokinetic parameters relative to RIF 600a
Pharmacokinetic
parameter
Adjusted geometric mean for regimen: Ratio of adjusted geometric mean
point estimate (90% CI)
(day 26 vs day 6)
ATV/RTV/RIF 300/100/600
(day 26; n  16)
RIF 600 mg
(day 26; n  14)
AUC(TAU) (ng  h/ml) 46,571.8 31,267.7 1.49 (1.20, 1.85)
Cmax (ng/ml) 10,613.1 8,057.6 1.32 (1.09, 1.59)
ATV/RTV/RIF 300/200/600
(day 26; n  17)
RIF 600 mg
(day 26; n  14)
AUC(TAU) (ng  h/ml) 49,483.9 31,267.7 1.58 (1.28, 1.96)
Cmax (ng/ml) 11,222.6 8,057.6 1.39 (1.15, 1.68)
ATV/RTV/RIF 400/200/600
(day 26; n  14)
RIF 600 mg
(day 26; n  14)
AUC(TAU) (ng  h/ml) 51,257.0 31,267.7 1.64 (1.31, 2.05)
Cmax (ng/ml) 10,983.3 8,057.6 1.36 (1.12, 1.66)
a n  number of subjects.
TABLE 5. Safety results
Parameter
No. of subjects (%) for regimen:
ATV 400 ATV/RTV300/100
ATV/RTV/RIF
300/100/600
ATV/RTV/RIF
300/200/600
ATV/RTV/RIF
400/200/600
RIF
600
No. of deaths 0 0 0 0 0 0
No. of discontinuations due to AEs 0 4 (8) 0 0 0
No. of serious AEs 0 0 0 0 0 0
Total no. of AEs 39 (74) 47 (90) 16 (94) 16 (94) 14 (100) 17 (94)
No. of subjects with:
Jaundice 4 (8) 6 (12) 0 0 0 0
Total bilirubin  grade 2 (5  ULN) 21 (40) 45 (87) 5 (29) 13 (76) 9 (64) 0
ALT/AST grade 2 (2.6 to 5  ULN) 1 (2) 0 0 1 (6) 1 (6) 1 (6)
ALT/AST grade 3/4 (5  ULN) 0 0 0 1 (6) 1 (6) 0
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29 	M in vitro (16). Since RIF and des-RIF are not CYP3A4
substrates, the increased exposures to RIF and des-RIF were
unexpected (3). However, this observation of increased expo-
sures for RIF was also noted with indinavir and RIF where RIF
AUC was increased 73% (9). From previous reports, RTV has
not been noted to increase RIF exposures (12). Therefore, it is
possible that other mechanisms, such as competition between
ATV and RIF for biliary secretion or transporters other than
P-gp, may play a role in the increased RIF exposures observed
with coadministration of ATV.
The observation of elevated liver transaminase levels in sev-
eral previously reported studies in which RIF was coadminis-
tered with the PIs saquinavir or lopinavir/ritonavir (6, 11) has
raised interest in the relative contributions of PIs and RIF in
the induction of increased transaminase levels. As such, the
design of the present study addressed this concern by intro-
ducing a parallel cohort that followed study procedures similar
to those of other cohorts but did not receive any drug on days
1 to 16 and received RIF only on days 17 to 26. In the present
study, the incidences of transaminase elevation were infre-
quent and not treatment related. Most reported transaminase
increases were grade 1 in severity. Only a slight increase in the
frequency of grade 1 to 3 severity elevations in ALT levels was
noted in treatment groups where RIF was dosed with 200 mg
of RTV (Table 5). AE occurrence was comparable across
treatments, with the incidence of jaundice (icterus), headaches,
fatigue, and dizziness being more prevalent in treatments ATV
400 and ATV/RTV 300/100 and chromaturia being more prev-
alent in RIF-containing regimens, as expected.
The most frequently observed laboratory abnormality in the
ATV-containing regimens was elevated total bilirubin. Almost
all subjects were noted to have elevated bilirubin levels while
receiving the ATV 400 or ATV/RTV 300/100 regimens, includ-
ing many of grade 3/4 severity. This observation was not un-
expected since these subjects were exposed to undiminished
levels of ATV in these two treatment groups and to higher
ATV exposures over a longer dosing period for treatment
ATV/RTV 300/100. Although ATV exposures were decreased
with RIF coadministration in treatments ATV/RTV/RIF 300/
100/600, ATV/RTV/RIF 300/200/600, and ATV/RTV/RIF
400/200/600, the frequency of sample collection and lack of a
washout period after the ATV/RTV 300/100 treatment en-
sured that bilirubin elevations would still be observed in the
RIF-containing regimens. Bilirubin levels were shown to re-
turn to within normal limits with follow-up. This reversal is
consistent with that seen after the withdrawal of ATV in other
healthy-population studies. ATV is known to bind, in a pre-
dominantly competitive manner, the bilirubin glucuronidating
isozyme, UGT 1A1. There is no indication from preclinical and
clinical data collected to date that the increases in total biliru-
bin represent a signal for a hepatotoxic process.
As expected, bilirubin levels were decreased to within the
normal range with the addition of RIF. It is difficult to esti-
mate, however, what proportion of the decrease is due to
decreased ATV exposures versus that due to the reported
inductive effect of RIF on UGT1A1 (7).
In summary, the treatment regimens ATV/RTV/RIF 300/
100/600, ATV/RTV/RIF 300/200/600, and ATV/RTV/RIF
400/200/600 were unable to fully counteract the inductive prop-
erties of RIF. The increases in RIF and des-RIF concentra-
tions were unexpected with ATV and RTV coadministration
and require further investigation. Nonetheless, RIF should not
be coadministered with ATV and RTV using the studied reg-
imens in HIV-infected patients due to the potential for re-
duced ATV exposures and the possibility for subsequent de-
creased viral susceptibility to ATV. However, the results of the
present study allow for further exploration of alternate dosing
strategies of ATV and RTV with RIF.
REFERENCES
1. Bergshoeff, A. S., T. F. Wolfs, S. P. Geelen, and D. M. Burger. 2003. Ritona-
vir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use. Ann.
Pharmacother. 37:521–525.
2. Boffito, M., E. Acosta, D. Burger, C. V. Fletcher, C. Flexner, R. Garaffo, G.
Gatti, M. Kurowski, C. F. Perno, G. Peytavin, M. Regazzi, and D. Back. 2005.
Therapeutic drug monitoring and drug-drug interactions involving antiret-
roviral drugs. Antivir. Ther. 10:469–477.
3. Burman, W. J., K. Gallicano, and C. Peloquin. 2001. Comparative pharma-
cokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Phar-
macokinet. 40:327–341.
4. Corbett, E. L., C. J. Watt, N. Walker, D. Maher, B. G. Williams, M. C.
Raviglione, and C. Dye. 2003. The growing burden of tuberculosis: global
trends and interactions with the HIV epidemic. Arch. Intern. Med. 163:
1009–1021.
5. Goldsmith, D., and C. Perry. 2003. Atazanavir. Drugs 63:1679–1693.
6. Grange, S., M. Schutz, C. Schmitt, M. Riek, and E. Gaudel-Ehrhart. 2005.
Unexpected hepatotoxicity observed in a healthy volunteer study on the
effects of multiple dose rifampicin on the steady-state pharmacokinetics of
ritonavir-boosted saquinavir and vice versa, abstr. 35. Sixth International
Workshop on Clinical Pharmacology of HIV Therapy, Montreal, Quebec,
Canada, 28 to 30 April 2005.
7. Greiner, B., M. Eichelbaum, P. Fritz, H. P. Kreichgauer, O. von Richter, J.
Zundler, and H. K. Kroemer. 1999. The role of intestinal P-glycoprotein in
the interaction of digoxin and rifampin. J. Clin. Investig. 104:147–153.
8. Hariparsad, N., S. C. Nallani, R. S. Sane, D. J. Buckley, A. R. Buckley, and
P. B. Desai. 2004. Induction of CYP3A4 by efavirenz in primary human
hepatocytes: comparison with rifampin and phenobarbital. J. Clin. Pharma-
col. 44:1273–1281.
9. Jaruraatanasirikul, S., and S. Sriwiriyajan. Effect of indinavir on the phar-
macokinetics of rifampicin in HIV-infected patients. J. Pharm. Pharmacol.
53:409–412.
10. King, J. R., H. Wynn, R. Brundage, and E. P. Acosta. 2004. Pharmacokinetic
enhancement of protease inhibitor therapy. Clin. Pharmacokinet. 43:291–
310.
11. La Porte, C. J., E. P. Colbers, R. Bertz, D. S. Voncken, K. Wikstrom, M. J.
Boeree, P. P. Koopmans, Y. A. Hekster, and D. M. Burger. 2004. Pharma-
cokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in
healthy volunteers. Antimicrob. Agents Chemother. 48:1553–1560.
12. Moreno, S., D. Podzamczer, R. Blazquez, J. A. Iribarren, E. Ferrer, J.
Reparaz, J. M. Pena, E. Cabrero, and L. Usan. 2001. Treatment of tuber-
culosis in HIV-infected patients: safety and antiretroviral efficacy of the
concomitant use of ritonavir and rifampin. AIDS 15:1185–1187.
13. Moyle, G. J., and D. Back. 2001. Principles and practice of HIV-protease
inhibitor pharmacoenhancement. HIV Med. 2:105–113.
14. Musial, B. L., J. K. Chojnacki, and C. I. Coleman. 2004. Atazanavir: a new
protease inhibitor to treat HIV infection. Am. J. Health Syst. Pharm. 61:
1365–1374.
15. O’Mara, E., V. Mummaneni, M. Bifano, D. Randall, H. Uderman, L. Knox,
and M. Geraldes. 2001. Steady-state pharmacokinetic interaction study be-
tween BMS-232632 and ritonavir in healthy subjects, abstr. 740. Eighth
Conference on Retrovirus and Opportunistic Infections, Chicago, Ill., 4 to 8
February 2001.
16. Perloff, E. S., S. X. Duan, P. R. Skolnik, D. J. Greenblatt, and L. L. von
Moltke. 2005. Atazanavir: effects on P-glycoprotein transport and CYP3A
metabolism in vitro. Drug Metab. Dispos. 33:764–770.
17. Scott, J. D. 2005. Simplifying the treatment of HIV infection with ritonavir-
boosted protease inhibitors in antiretroviral-experienced patients. Am. J.
Health Syst. Pharm. 62:809–815.
18. Tacket, D., M. Child, S. Agarwala, M. Geraldes, M. Geiger, B. Laura, and E.
O’Mara. 2003. Atazanavir: a summary of two pharmacokinetic (PK) drug
interaction studies in healthy subjects, abstr. 543. Tenth Conference on
Retroviruses and Opportunistic Infections, Boston, Mass.
19. Veldkamp, A., R. M. W. Hoetelmans, J. H. Beijnen, J. W. Mulder, and P. L.
Meenhorst. 1999. Ritonavir enables combined therapy with rifampin and
saquinavir. Clin. Infect. Dis. 29:1586.
3342 BURGER ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 N
ovem
ber 2, 2012 by Universiteitsbibliotheek
http://aac.asm
.org/
D
ow
nloaded from
 
